While OS was not significantly improved, there appeared to be a strong trend toward greater benefit in those patients receiving T-VEC relative to GM-CSF alone, particularly in those with regional disease only.
1
—
—
While OS was not significantly improved, there appeared to be a strong trend toward greater benefit in those patients receiving T-VEC relative to GM-CSF alone, particularly in those with regional disease only.